Advisors Asset Management Inc. Boosts Stake in IQVIA Holdings Inc. (NYSE:IQV)

Advisors Asset Management Inc. boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 74.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,845 shares of the medical research company’s stock after acquiring an additional 1,213 shares during the period. Advisors Asset Management Inc.’s holdings in IQVIA were worth $674,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Canada Pension Plan Investment Board grew its position in shares of IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after purchasing an additional 211,653 shares in the last quarter. Farallon Capital Management LLC grew its holdings in IQVIA by 3.1% in the 2nd quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock valued at $618,046,000 after buying an additional 86,870 shares in the last quarter. Impax Asset Management Group plc increased its stake in shares of IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of IQVIA by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 1,514,237 shares of the medical research company’s stock worth $320,170,000 after acquiring an additional 11,715 shares during the period. Finally, Dimensional Fund Advisors LP grew its holdings in shares of IQVIA by 5.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,197,084 shares of the medical research company’s stock valued at $253,125,000 after purchasing an additional 60,827 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Argus upgraded shares of IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Redburn Atlantic initiated coverage on IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Robert W. Baird cut their target price on IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. TD Cowen decreased their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.50.

IQVIA Trading Down 1.4 %

NYSE:IQV opened at $201.24 on Wednesday. The stock has a fifty day moving average price of $221.18 and a 200 day moving average price of $226.75. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The firm has a market cap of $36.53 billion, a PE ratio of 26.41, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.